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Mendelian randomizationBackground: Anemia is a known adverse prognostic factor among patients with cardiovascular diseases.
We investigated whether the hemoglobin level was associated with the rhythm outcome after atrial fib-
rillation (AF) catheter ablation (AFCA).
Methods: We included 2627 patients who underwent AFCA and a guidelines-based rhythm follow-up
(age 58 ± 10.9 years, 73% men, 30.6% with persistent AF), and evaluated the association of pre-AFCA ane-
mia (haemoglobin <13 g/dL in men and <12 g/dL in women) and rhythm outcomes. We studied the mech-
anistic relationship between anemia and AF recurrence using a Mendelian randomization analysis (1775
subjects with genome-wide association study) after reviewing already proven 12 hemoglobin-associated
genetic polymorphisms.
Results: The body mass index, paroxysmal AF, warfarin use, and baseline red cell distribution width were
independently associated with anemia in patients with AF. During a 23-month follow-up (interval OR 9–
48 months), the clinical AF recurrence rate was significantly higher in patients with than without anemia
(log-rank p = 0.001; propensity score-matched log-rank p = 0.004). This pattern was more significant in
male patients (Log-rank p < 0.001) or patients with paroxysmal AF (Log-rank p < 0.001). Anemia (hazard
ratio [HR] 1.45 [1.17–1.80], p = 0.001), left atrial diameter (HR 1.03 [1.01–1.04], p < 0.001), a female sex
(HR 1.17 [1.00–1.36], p = 0.047), and persistent AF (HR 1.58 [1.36–1.84], p < 0.001) were independently
associated with post-AFCA clinical recurrence. In the Mendelian randomization, we could not find a sig-
nificant direct causal relationship between anemia and AF recurrence at the genetic level.
Conclusions: Pre-AFCA anemia is an independent predictor of post-AFCA clinical recurrence, especially in
male patients, without a genetically direct causal relationship.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial fibrillation (AF) is a chronic degenerative rhythm disorder
and has been known to be associated with heart failure, strokes,
and dementia [1]. AF usually occurs in elderly people with multiple
comorbidities, and anemia is potentially likely to be present in
patients undergoing anticoagulant therapy for stroke prevention.
Anemia is a poor prognostic factor for cardiovascular diseases such
as heart failure, coronary artery disease, and arteriosclerosis [2–4].
However, studies on the effects of anemia on the AF prognosis are
limited. Recently, there have been reports of an increased risk of
major bleeding and mortality when anemia occurs in association
with AF in patients undergoing anticoagulation therapy [5,6]. How-ever, no study has evaluated the direct link between anemia and
the rhythm control outcomes of AF.
Radiofrequency catheter ablation of AF is an effective rhythm
control strategy in patients with AF refractory to antiarrhythmic
drugs as a guideline-based therapy with a proven efficacy and
safety [7,8]. A few small clinical studies have shown that the red
cell distribution width (RDW), another hematological parameter,
has a predictive value for the rhythm outcome after cryoballoon
ablation of AF; however, its mechanism is unknown [9–11]. Hemo-
globin or anemia, the evaluation of which is included in the pre-
procedural routine blood tests, has never been suggested as a sur-
rogate marker of AF recurrence after AF catheter ablation (AFCA).
The Mendelian randomization tests the mechanistic causal rela-
tionship of a modifiable surrogating parameter among the multiple
confounding factors on a clinical outcome by measuring the
genetic variations of known function [12,13]. The purpose of this
study was to investigate the effect of pre-procedural anemia on
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attempted to prove the mechanistic causal relationship between
anemia and the rhythm outcome of AFCA at the genetic level by
using the Mendelian randomization method.2. Methods
Data supporting the findings of this study are available from the
corresponding author upon reasonable request.
2.1. Study population
The study population consisted of 2744 patients who under-
went AFCA for paroxysmal AF or persistent AF for the first time
between January 2009 and January 2019 at Yonsei University
Hospital. We included 2627 patients in this study after excluding
117 patients whose follow-up duration was <3 months. The study
complied with the Declaration of Helsinki and was approved by the
Institutional Review Board at the Yonsei University Health System.
Written informed consent was obtained from all patients for inclu-
sion in the Yonsei AF Ablation Cohort Database (ClinicalTrials.gov
NCT02138695). The indication for AFCA complied with the latest
guidelines. The exclusion criteria were as follows: (1) permanent
AF refractory to electrical cardioversion; (2) structural heart dis-
ease other than left ventricular hypertrophy, such as significant
valvular heart disease of grade 2, hypertrophic/ischemic/dilated
cardiomyopathy, and congenital heart diseases; (3) a history of
prior AFCA or cardiac surgery; and (4) insufficient examination
results at baseline or loss to follow-up within 3 months after the
AFCA. All antiarrhythmic drugs were discontinued for at least five
half-lives, and amiodarone was stopped at least 4 weeks before the
procedure. Anticoagulation therapy was maintained before cathe-
ter ablation. All patients underwent transthoracic echocardiogra-
phy and three-dimensional spiral heart computed tomography
for the evaluation of the atrial anatomy and atrioventricular func-
tion before the AFCA.
2.2. Radiofrequency catheter ablation
An open-irrigated, 3.5-mm-tip deflectable catheter (Celsius/
Smart Touch SF [Johnson & Johnson Inc., Diamond Bar, CA, USA]
or Coolflex/Flexibility [St. Jude Medical Inc., Minnetonka, MN,
USA]; 30–35 W, 47 C) was used for the AFCA. All patients initially
underwent a circumferential pulmonary vein isolation and cavo-
tricuspid isthmus ablation. We added linear ablation, such as a roof
line, posterior inferior line, anterior line, or superior vena cava to
the septal line, or a complex fractionated electrogram-guided abla-
tion based on the operator’s discretion, especially in patients with
persistent or longstanding persistent AF. The procedure ended
when there was no immediate recurrence of AF within 10 min after
cardioversion with isoproterenol provocation (5–10 lg/min). Non-
pulmonary vein focus triggers under an isoproterenol infusion
were also ablated as much as possible, if they were consistent
and reproducible.
2.3. Post-ablation management and follow-up
Patients visited the outpatient clinic regularly at 1, 3, 6, and
12 months and then every 6 months thereafter or whenever symp-
toms occurred after the AFCA. All patients underwent electrocar-
diography (ECG) during every visit and 24-h Holter recordings at
3 and 6 months and every 6 months thereafter, according to the
2012 HRS/EHRA/ECAS Expert Consensus Statement guidelines
[14]. Holter monitoring or event monitor recordings were obtained
when the patients reported symptoms of palpitations suggestive ofan arrhythmia recurrence. The Holter analysis and adjudication
were performed by an individual blinded to the study group
assignment. AF recurrence was defined as any episode of AF or
atrial tachycardia (AT) of at least 30 s in duration. Any ECG docu-
mentation of an AF recurrence within a 3-month blanking period
was diagnosed as an early recurrence, and an AF recurrence of
more than 3 months after the procedure, was diagnosed as a clin-
ical recurrence.
2.4. Laboratory assessment
Blood samples were drawn within 1 day before the AFCA. Com-
plete blood cell counts were assessed using an XE-2100 automated
hematology analyzer (Sysmex Inc., Kobe, Japan). The reference
range for a normal hemoglobin level was 13.0–17.4 g/dL. Anemia
was defined as a hemoglobin level of <13 g/dL in men and <12 g/
dL in women. The plasma blood urea nitrogen, creatinine, and
RDW were also evaluated before the procedure. The estimated
glomerular filtration ration (eGFR) was calculated using the
Cockcroft-Gault equation. The patient baseline characteristics,
comorbidities, and therapeutic details were obtained from the hos-
pital medical records.
2.5. DNA genotyping
Among the 2627 patients included in this study, a genome-wide
association study (GWAS) was performed in 1775 patients who
provided informed consent for a genetic study. The genomic DNA
was extracted from peripheral blood samples by using a Quick-
Gene DNA whole blood kit S with QuickGene mini80 (KURABO,
Osaka, Japan). The genomic DNA samples were analyzed using
the Axiom Precision Medicine Research Array (PMRA) (Ther-
mofisher Scientific, Waltham, MA, USA).
After quality control of the PMRA DNA chip, 403,402 genotyped
SNPs were available. Next, for the Mendelian randomization anal-
ysis, we chose 12 SNPs, which had been previously proven to be
related to anemia, including 2 proxy SNPs (linkage disequilibrium,
r2 > 0.8) in 1775 patients.: TF (rs1799852), TF (rs8177240), TF,
RAB6B (rs6765093 proxy SNP, r2 = 1 with rs2280673 in 1000 Gen-
ome Asians), HFE (rs1799945), CCND3 (rs11970772), HBS1L, MYB
(rs4895441), NAT2, PSD3 (rs4921915), ABO, SURF6 (rs651007),
ARNTL (rs6486121), FADS2 (rs174577), TEX14 (rs412000 proxy
SNP, r2 = 1 with rs411988 in 1000 Genome Asians), and TMPRSS6
(rs855791) [15,16].
2.6. Statistical analysis
Continuous variables were described as means with standard
deviations (normal distribution), and variables with a non-
normal distribution were described as medians and interquartile
ranges. The Student’s t-test and Mann-Whitney U test were used
to compare continuous variables. Categorical variables were com-
pared using the chi-square test or Fisher’s exact test. Univariable
Spearman correlation and partial correlation were used to evaluate
the magnitude and significance of the relationships among the
continuous variables. Multiple Cox proportional hazard analyses
were performed to identify the independent predictors of a clinical
recurrence of AF after AFCA. The Kaplan-Meier method was used to
estimate the event-free survival with a log-rank test. Given the
observational nature of our study, patients with anemia and with-
out anemia were not comparable. To reduce the influence of con-
founding factors, we also performed a propensity score matching
analyses adjusted by multiple covariates.
The selected SNPs were evaluated through a Mendelian ran-
domization analysis. The causal effect of hemoglobin on the clinical
recurrence of AF was quantified using a two-stage least square
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(wGRS) as an instrument, by using two selected SNPs that were
associated with the hemoglobin level in the male population. The
wGRS was calculated as the sum of the risk alleles multiplied by
the estimated b-coefficient (effect size) for each SNP.
Data analyses were performed using SPSS (SPSS Inc., Chicago, IL,
USA), R version 3.5.1 (R Foundation for Statistical Computing,
Vienna, Austria), and Stata version 15.1 (StataCorp, College Station,
TX, USA) software. Two-tailed p-values of <0.05 were considered to
indicate statistical significance.3. Results
3.1. Patient characteristics related to baseline anemia
A total of 2627 patients who were followed up for >3 months
after the AFCA were evaluated in this study. Of those, 252 patients
(9.6%) had baseline anemia before the AFCA procedure (Supple-
mentary Fig. 1). Table 1 summarizes the baseline demographic,
clinical, echocardiographic, and laboratory characteristics between
the baseline anemia and non-anemia groups. Patients with anemia
and AF were older (p < 0.001), had higher proportions of women
(p < 0.001), individuals with paroxysmal AF (p = 0.006), non-Table 1





Age, (years) 59 (51, 66) 5
Female, n (%) 708 (27.0) 6
BMI, (kg/m2) 24.8 (23.0, 26.8) 2
Duration of AF, (day) 23 (9, 48) 2
Paroxysmal AF, n (%) 1823 (69.4) 1
Clinical recurrence, n (%) 870 (33.1) 7
Smoking, n (%)
Never 1608 (61.2) 1
Former 758 (28.9) 6
Current 259 (9.9) 2
Alcohol, n (%)
Never 1298 (49.4) 1
Former 533 (20.3) 4
Current 795 (30.3) 7
Comorbidities
Hypertension, n (%) 1204 (45.8) 1
Diabetes, n (%) 394 (15.0) 3
Prior stroke/TIA, n (%) 298 (11.3) 2
Vascular disease, n (%) 302 (11.5) 2
CHA2DS2-VASc score 1 (0, 3) 1
*Anticoagulation, n (%)
Warfarin 1359 (51.7) 1
NOAC 1231 (46.9) 1
yAnticoagulation, n (%)
Warfarin 634 (53.2) 5
NOAC 557 (46.8) 4
Laboratory data, baseline
BUN, (mg/dL) 15.7 (13.0, 18.8) 1
Creatinine, (mg/dL) 0.9 (0.8, 1.0) 0
eGFR, (mL/min/1.73 m2) 84.7 (69.0, 103.8) 8
Hemoglobin, (g/dL) 14.4 (13.4, 15.4) 1
RDW, (%) 12.9 (12.5, 13.4) 1
Echocardiographic data
LA diameter, (mm) 41 (37, 45) 4
LVEF, (%) 64 (59, 68) 6
Mean LA pressure, (mmHg) 12 (9, 17) 1
The data are presented as the number (%) and median (interquartile). Non-parametric c
analysed through a Mann-whitney u test.
Abbreviations: AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; BMI, body
LA, left atrial; LVEF, left ventricular ejection fraction; NOAC, non-vitamin K oral anticoa
* All patients were analysed regardless of the CHA2DS2-VASc score.
y Patients with a CHA2DS2-VASc score of 0 and 1 were excluded, n = 1191.drinkers (p = 0.004), non-smokers (p < 0.001), and warfarin users
(p < 0.001), and had a lower body mass index (BMI, p < 0.001) or
eGFR (p < 0.001). They also had higher CHA2DS2-VASc scores
(p < 0.001), higher prevalence of hypertension (p = 0.008), diabetes
(p < 0.001), a prior stroke or transient ischemic attack (TIA;
p = 0.009), or vascular disease (p < 0.001), and a higher mean left
atrial pressure (p = 0.007) and baseline RDW (p < 0.001) than their
counterparts. In a multivariate logistic regression analysis (Supple-
mentary Table 1), the BMI (OR 0.88 [0.83–0.93], p < 0.001), parox-
ysmal AF (OR 1.95 [1.37–2.79]. p < 0.001), warfarin use (OR 1.42
[1.05–1.92], p = 0.023), and baseline RDW (OR 1.97 [1.70–2.27],
p < 0.001) were independently associated with anemia in patients
with AF. Iron deficiency anemia (7.1%), malignancy (7.9%), autoim-
mune disease (2.0%), and chronic kidney disease with a grade 3
(34.4%) were suggested as potential causes of anemia. In 48.6% of
the patients in whom the exact cause of the anemia could not be
confirmed, they did not have any evidence of bleeding or a specific
hematologic disorder. Those patients had a mild degree of normo-
cytic anemia (Hb 11.6 ± 1.0 g/dL, MCV 92.7 ± 6.01 fL), and we did
not perform a complete hematologic evaluation including the iron
kinetics in those patients. Therefore, the cause of the anemia was
mostly considered to be an unspecified category. There was no sig-
nificant difference in the ORBIT-AF bleeding risk score between the






8 (51, 66) 65 (57, 72) <0.001
04 (25.4) 104 (41.3) <0.001
4.9 (23.2, 26.9) 23.4 (21.9, 25.6) <0.001
4 (9, 50) 19 (8, 36) 0.147
629 (68.6) 194 (77.0) 0.006
57 (31.9) 113 (44.8) <0.001
<0.001
429 (60.2) 179 (71.0)
96 (29.3) 62 (24.6)
48 (10.5) 11 (4.4)
0.004
152 (48.5) 146 (57.9)
82 (20.3) 51 (20.2)
40 (31.2) 55 (21.8)
068 (45.0) 136 (54.0) 0.008
36 (14.2) 58 (23.0) <0.001
56 (10.8) 42 (16.7) 0.009
53 (10.7) 49 (19.4) <0.001
(0, 2) 2 (1, 4) <0.001
0.001
203 (51.3) 156 (63.2)
140 (48.7) 91 (36.8)
0.007
29 (51.7) 105 (62.9)
95 (48.3) 62 (37.1)
5.7 (13.1, 18.7) 16.9 (12.9, 21.4) 0.004
.9 (0.8, 1.0) 0.9 (0.7, 1.1) 0.646
7.1 (71.3, 106.4) 70.8 (52.6, 89.7) <0.001
4.6 (13.7, 15.6) 11.8 (11.1, 12.5) <0.001
2.9 (12.5, 13.3) 13.5 (12.9, 14.3) <0.001
1 (37, 45) 42 (38, 46) 0.063
4 (59, 68) 63 (59, 69) 0.874
2 (9, 16) 14 (9, 19) 0.007
ontinuous variables which were evaluated by Kolmogorov-Smimov method, were
mass index; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate;
gulants; RDW, red blood cell distribution widths; TIA, transient ischemic attack.
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During a follow-up of 23 months (IQR 9–48 months), the rate of
an AF clinical recurrence was significantly higher in the patients
with anemia than in those without (log-rank p = 0.001; Fig. 1A).
Even after propensity score-matching with respect to the age,
BMI, sex, AF type, anticoagulation, history of smoking, history of
alcohol consumption, hypertension, diabetes, prior stroke/TIA, vas-
cular disease, CHA2DS2-VASc score, left atrial diameter, left ventric-
ular ejection fraction, and baseline eGFR (Supplementary Table 3),
this finding was consistent (log-rank p = 0.004; Fig. 1B). This pat-
tern was more significant in male patients (log-rank p < 0.001),
patients with paroxysmal AF (log-rank p < 0.001), and the patients
both younger than 60 years (log rank p = 0.005) and older than
60 years (log rank p = 0.031; Supplementary Fig. 2).
The AF recurrence group had a longer AF duration (p = 0.008),
lower prevalence of paroxysmal AF (p < 0.001) and prior stroke
or TIA (p = 0.036), and higher proportion of warfarin users
(p < 0.001) than those remained in sinus rhythm (Supplementary
Table 4). The left atrial diameter (p < 0.001) and mean left atrial
pressure (p = 0.004) were greater in the clinical recurrence group.
The pre-AFCA hemoglobin level was significantly lower (p < 0.001),
RDW higher (p < 0.001), and anemia more commonly found
(p < 0.001) in patients with clinical recurrence than in those who
remained in sinus rhythm. In a multivariate Cox regression analy-
sis, paroxysmal AF (HR 0.63 [0.54–0.73], p < 0.001), the left atrial
diameter (HR 1.03 [1.01–1.04], p = 0.001), a female sex (HR 1.17
[1.00–1.36], p = 0.047, and anemia (HR 1.45 [1.17–1.80],
p = 0.001) were independently associated with the clinical recur-
rence of AF after AFCA (Table 2).
3.3. Indirect causal relationship between anemia and AF recurrence
Among the 2627 total patients, GWAS data were available in
1775 (67.6%) patients (Supplementary Fig. 1). Before the Men-
delian randomization, an association between the hemoglobin
level and clinical recurrence was consistently observed in this
group with genetic data (Fig. 2A). Of the 12 SNPs previously
reported to be associated with anemia, rs651007 (ABO gene at
9q34.2) was associated with the hemoglobin level in model 1 (ad-
justed for the age and sex, F-statistics = 221.9, p = 0.047) and
rs174577 (FADS2 gene at 11q12.2) was associated with the hemo-
globin level in model 2 (adjusted for the age, BMI, sex, AF type, his-Fig. 1. The Kaplan-Meier analysis of AF-free survival rates in patients with and without b
population (B).tory of smoking and alcohol consumption, hypertension, diabetes,
prior stroke/TIA, CHA2DS2-VASc score, left atrial diameter, left ven-
tricular ejection fraction, baseline eGFR, and RDW; F-
statistics = 56.7, p = 0.042; Fig. 2B). None of the 12 SNPs exhibited
a significant odds ratio between the anemia and non-anemia (Data
not shown). However, a single instrument variable analysis using a
two-stage least square regression did not show an association
between the hemoglobin level and AF clinical recurrence (Fig. 2C
and D).4. Discussion
4.1. Main findings
In this study, we explored the relationship between pre-
procedural anemia and the rhythm outcome of AFCA. We found
that 9.6% of the included patients had anemia, which was associ-
ated with a low BMI, paroxysmal AF, warfarin use, and high
RDW. During the median 23 month follow-up, anemia was inde-
pendently associated with a clinical recurrence of AF, especially
in male patients and patients with paroxysmal AF. However, we
did not find a direct causal relationship between anemia and a
post-AFCA recurrence at the genetic level by using the Mendelian
randomization.4.2. Anemia and cardiovascular disease
Anemia is an independent predictor of adverse cardiovascular
outcomes in various cardiovascular diseases, including heart fail-
ure, coronary artery disease, and atherosclerosis [2–4]. The pres-
ence of anemia has been known to increase the heart failure
mortality and hospitalization rates [3,17–22], the risk of acute
coronary syndrome [2,23], and the incidence of thromboembolic
or bleeding events in patients with AF under anticoagulation
[5,6,24]. Multiple mechanisms, such as neurohormonal, hemody-
namic, and renal alterations, seem to contribute to poor outcomes
in anemic patients with cardiovascular disease. Anemia has been
shown to have adverse effects on the myocardial and large arterial
hypertrophic remodeling that occurs owing to sustained increases
in the cardiac output [25–27]. However, it is not clear whether ane-
mia has a causal relationship with poor cardiovascular outcomes or
if it is a simple marker of more advanced disease.aseline anemia within the overall population (A) and the propensity score matched
Table 2
Cox regression analysis for the predictors of a clinical recurrence of AF after AFCA.
Univariable analysis Multivariable model 1* Multivariable model 2y
Unadjusted HR (95% CI) p value Adjusted HR (95%CI) p value Adjusted HR (95% CI) p value
Age 1.00 (0.99–1.01) 0.722 0.99 (0.99–1.00) 0.104 0.99 (0.99–1.00) 0.061
BMI 1.01 (0.99–1.04) 0.227 1.00 (0.98–1.03) 0.864 1.00 (0.98–1.03) 0.753
Female 1.13 (0.97–1.30) 0.114 1.17 (1.00–1.36) 0.047 1.02 (0.86–1.21) 0.800
Paroxysmal AF 0.57 (0.50–0.66) <0.001 0.69 (0.58–0.82) <0.001 0.67 (0.57–0.80) <0.001
Warfarin vs. NOAC 1.19 (1.03–1.39) 0.020 1.10 (0.94–1.28) 0.240 1.09 (0.94–1.28) 0.263
Smoking (vs. Never)
Former 0.93 (0.80–1.09) 0.374
Current 1.07 (0.86–1.34) 0.555
Alcohol (vs. Never)
Former 0.90 (0.75–1.07) 0.239
Current 0.90 (0.78–1.05) 0.197
Hypertension 1.03 (0.90–1.17) 0.695
Diabetes 1.04 (0.87–1.25) 0.659
Prior stroke/TIA 1.15 (0.94–1.40) 0.167
Vascular disease 1.02 (0.84–1.25) 0.812
CHA2DS2-VASc score 1.03 (0.99–1.07) 0.170
LA diameter 1.04 (1.03–1.05) <0.001 1.03 (1.01–1.04) <0.001 1.03 (1.01–1.04) 0.001
LVEF 0.99 (0.99–1.00) 0.102
Extra-PV LA ablation 1.55 (1.36–1.77) <0.001 1.17 (0.98–1.38) 0.076 1.16 (0.97–1.37) 0.098
CTI ablation 0.87 (0.69–1.09) 0.221
Baseline eGFR 1.00 (0.99–1.00) 0.722
Baseline hemoglobin 0.93 (0.89–0.97) 0.001 0.90 (0.86–0.95) <0.001
Baseline RDW 1.09 (1.02–1.16) 0.014 1.01 (0.94–1.09) 0.804 1.00 (0.93–1.08) 0.913
Baseline anemia 1.41 (1.16–1.72) 0.001 1.45 (1.17–1.80) 0.001
CI = confidence interval, HR = Hazard ratio. The other abbreviations are defined in Table 1.
Abbreviations: PV, pulmonary vein; CTI, cavo-tricuspid isthmus.
* Model 1; Adjusted for the age, BMI, sex, AF types, anticoagulation, LA diameter, Extra-PV LA ablation, CTI ablation, baseline RDW, and anemia.
y Model 2; Adjusted for the age, BMI, sex, AF types, anticoagulation, LA diameter, Extra-PV LA ablation, CTI ablation, baseline RDW, and haemoglobin.
Fig. 2. Comparison of the baseline hemoglobin level between the clinical recurrence and non-recurrence groups in the overall population (A). A Mendelian randomization
instrumental variable analysis with a two-stage least square estimation in the overall population (B–D).
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Studies about the prognosis of anemia in association with AF
are still limited. In the ARISTOTLE sub-study, Westenbrink et al.
[5] reported that anemia is associated with bleeding and a high
mortality, and not with a stroke risk, in patients under anticoagu-
lation for AF. Bonde et al. [6] performed a Danish registry analysis
and reported that moderate to severe anemia (hemoglobin < 6.83
mmol/L [11.0 g/dL]) was associated with major bleeding and a
lower time in a therapeutic range in patients with AF. In this ane-
mia group, oral anticoagulation was associated with major bleed-
ing but did not lower the stroke or systemic thromboembolic risk.
Although there have been small-scale studies on the association
of the RDW with the rhythm outcome after cryoballoon ablation of
AF [9–11], to the best of our knowledge, this study was the first to
report, with the largest number of patients, on the independent
association of anemia with the AFCA outcome. The RDW is known
to be a prognostic parameter in patients with heart failure, and this
study also confirmed its association with the AF rhythm outcome
after AFCA. However, the RDW is a parameter influenced by vari-
ous hematologic confounding factors, and hemoglobin was more
predictive of the rhythm outcome than the RDW in this study.
4.4. Potential mechanisms and the Mendelian randomization
In this study, anemia was more frequently found in patients
with multiple comorbidities and had statistically significant associ-
ations with a low BMI, paroxysmal AF, and warfarin use. However,
in 252 patients with anemia, the prevalence of iron deficiency ane-
mia was only 7.1% and chronic diseases such as chronic kidney dis-
ease grade 3, cancer, or inflammatory disease were observed in
44% of patients with anemia (Supplementary Table 2). Moreover,
no other relevant factors were found other than the hematologic
parameters after a propensity score matching for comorbidities
associated with anemia (Supplementary Table 3). It was difficult
to determine why the co-occurrence of anemia increased the
recurrence rate of AF after AFCA, especially in male patients or
patients with paroxysmal AF. Therefore, a Mendelian randomiza-
tion was performed to determine the causal relationship between
anemia and AF recurrence through a genetic study.
The Mendelian randomization is a method of using measured
variations in genes of known function to examine the causal effect
of a modifiable exposure on a disease in observational studies
[12,13]. In this study, we confirmed the existence of a significant
relationship between anemia and AF recurrence, and 2 of the 12
already proven anemia-associated genes showed a statistically sig-
nificant b-coefficient for anemia among the included patient group.
However, those two significant genes did not have a significant
relationship with AF recurrence in the two-stage least square
regression analysis. Therefore, the direct causal relationship
between anemia and AF recurrence has not been proven statisti-
cally and is presumed to be the result of indirect effects. Further
observational studies with more patients and more genes, or clin-
ical intervention studies, will be needed.
4.5. Limitations
The present study should be interpreted in the context of its
limitations. First, our study had an observational design and was
based on a single-center prospective cohort registry. Second, a
patient with anemia may seek more medical attention or even be
more symptomatic during AF, which leads to more patients being
classified into the recurrence group. Third, the exact cause of the
anemia was unknown in 48.6% of 252 patients with clinical ane-
mia. The baseline characteristics rather differed between the ane-
mia group and non-anemia group. Thereby, we used a propensityscore matching to attenuate the impact of the confounding factors,
and the results were consistent with the findings from the overall
population. Although we attempted to explain the contributing
mechanism to the causal relationship of anemia and AF recurrence,
we could not find a direct association.5. Conclusion
Pre-AFCA anemia was independently associated with a clinical
recurrence of AF, especially in male patients and patients with
paroxysmal AF. However, we did not find a direct causal relation-
ship between anemia and post-AFCA recurrence at the genetic
level using the Mendelian randomization.Acknowledgement
We would like to thank Mr. John Martin for his linguistic
assistance.Sources of Funding
This work was supported by grants (HI18C0070 and
HI19C0114) from the Ministry of Health and Welfare and a grant
(NRF-2017R1A2B4003983) from the Basic Science Research Pro-
gram of the National Research Foundation of Korea (NRF), which
is funded by the Ministry of Science, ICT, & Future Planning (MSIP).Declaration of Competing Interest
The authors declare that there is no conflict of interest.Appendix A. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ijcha.2020.100507.References
[1] V.L. Roger, A.S. Go, D.M. Lloyd-Jones, et al., Heart disease and stroke statistics—
2012 update: a report from the American Heart Association, Circulation 125
(2012) e2–e220.
[2] M.J. Sarnak, H. Tighiouart, G. Manjunath, B. MacLeod, J. Griffith, D. Salem, et al.,
Anemia as a risk factor for cardiovascular disease in the atherosclerosis risk in
communities (aric) study, J. Am. Coll. Cardiol. 40 (2002) 27–33.
[3] H.F. Groenveld, J.L. Januzzi, K. Damman, et al., Anemia and mortality in heart
failure patients: a systematic review and meta-analysis, J. Am. Coll. Cardiol. 52
(2008) 818–827.
[4] D.W. Brown, W.H. Giles, J.B. Croft, Hematocrit and the risk of coronary heart
disease mortality, Am. Heart J. 142 (2001) 657–663.
[5] B.D. Westenbrink, M. Alings, C.B. Granger, et al., Anemia is associated with
bleeding and mortality, but not stroke, in patients with atrial fibrillation:
Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial, Am. Heart J. 185 (2017) 140–149.
[6] A.N. Bonde, P. Blanche, L. Staerk, et al., Oral anticoagulation among atrial
fibrillation patients with anaemia: an observational cohort study, Eur. Heart J.
(2019) ehz155, https://doi.org/10.1093/eurheartj/ehz155 (Epub 2019 April 1).
[7] P. Kirchhof, S. Benussi, D. Kotecha, et al., 2016 ESC Guidelines for the
management of atrial fibrillation developed in collaboration with EACTS, Eur.
Heart J. 37 (2016) 2893–2962.
[8] C.T. January, L.S. Wann, J.S. Alpert, et al., 2014 AHA/ACC/HRS guideline for the
management of patients with atrial fibrillation, J. Am. Coll. Cardiol. 64 (2014)
e1–e76.
[9] H. Li, T. Liu, G. Xu, E. Liu, Z. Jiao, G. Li, Red blood cell distribution width and the
recurrence of atrial fibrillation after ablation in patients with paroxysmal non-
valvular symptomatic atrial fibrillation, Int. J. Cardiol. 203 (2016) 834–836.
[10] K.M. Gurses, M.U. Yalcin, D. Kocyigit, et al., Red blood cell distribution width
predicts outcome of cryoballoon-based atrial fibrillation ablation, J. Interv.
Card. Electrophysiol. 42 (2015) 51–58.
[11] T. Aksu, T. Guler, E. Golcuk, I. Erden, K. Ozcan, E. Baysal, Predictors of atrial
fibrillation recurrence after cryoballoon ablation, J. Blood Med. 6 (2015) 211–
217.
M. Kim et al. / IJC Heart & Vasculature 27 (2020) 100507 7[12] M.V. Holmes, M. Ala-Korpela, G.D. Smith, Mendelian randomization in
cardiometabolic disease: challenges in evaluating causality, Nat. Rev.
Cardiol. 14 (2017) 577–590.
[13] D.A. Bennett, M.V. Holmes, Mendelian randomisation in cardiovascular
research: an introduction for clinicians, Heart 103 (2017) 1400–1407.
[14] H. Calkins, K.H. Kuck, R. Cappato, et al., HRS/EHRA/ECAS expert consensus
statement on catheter and surgical ablation of atrial fibrillation:
recommendations for patient selection, procedural techniques, patient
management and follow-up, definitions, endpoints, and research trial
design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter
and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the
European Heart Rhythm Association (EHRA), a registered branch of the
European Society of Cardiology (ESC) and the European Cardiac Arrhythmia
Society (ECAS); and in collaboration with the American College of Cardiology
(ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm
Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the
governing bodies of the American College of Cardiology Foundation, the
American Heart Association, the European Cardiac Arrhythmia Society, the
European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia
Pacific Heart Rhythm Society, and the Heart Rhythm Society, Heart Rhythm. 9
(2012), 632-96.e621.
[15] B. Benyamin, A.F. McRae, G. Zhu, et al., Variants in TF and HFE explain ~40% of
genetic variant in serum transferrin levels, Am. J. Hum. Genet. 84 (2009) 60–
65.
[16] S.K. Ganesh, N.A. Zakai, F.J. van Rooij, et al., Multiple loci influence erythrocyte
phenotype in the CHARGE Consortium, Nat. Genet. 41 (2009) 1191–1198.
[17] I.S. Anand, Anemia and chronic heart failure, J. Am. Coll. Cardiol. 52 (2008)
501–511.[18] F. Formiga, D. Chivite, O. Castañer, N. Manito, J.M. Ramón, R. Pujol, Anemia in
new-onset congestive heart failure inpatients admitted for acute
decompensation, Eur. J. Intern. Med. 17 (2006) 179–184.
[19] R.S. Gardner, K.S. Chong, J.J. Morton, T.A. Mcdonagh, N-terminal brain
natriuretic peptide, but not anemia, is a powerful predictor of mortality in
advanced heart failure, J. Card. Fail. 11 (2005) S47–S53.
[20] J.-H. Lee, M.-S. Kim, E.J. Kim, et al., KSHF guidelines for the management of
acute heart failure: Part I. Definition, epidemiology and diagnosis of acute
heart failure, Korean Circ. J. 49 (2019) 1–21.
[21] Y.-D. Tang, S.D. Katz, The prevalence of anemia in chronic heart failure and its
impact on the clinical outcomes, Heart Fail. Rev. 13 (2008) 387–392.
[22] E. O’Meara, T. Clayton, M.B. McEntegart, et al., Clinical correlates and
consequences of anemia in a broad spectrum of patients with heart failure:
results of the candesartan in heart failure: assessment of reduction in
mortality and morbidity (CHARM) program, Circulation 113 (2006) 986–994.
[23] P.R. Lawler, K.B. Filion, T. Dourian, R. Atallah, M. Garfinkle, M.J. Eisenberg,
Anemia and mortality in acute coronary syndromes: a systematic review and
meta-analysis, Am. Heart J. 165 (2013) 143–153.
[24] K. Takabayashi, T. Unoki, H. Ogawa, M. Esato, Y.H. Chun, H. Tsuji, H. Wada, K.
Hasegawa, M. Abe, M. Akao, Clinical characteristics of atrial fibrillation
patients with anemia: from the Fushimi AF registry, Eur. Heart J. 34 (suppl
1) (2013) P389.
[25] M.A. Varat, R.J. Adolph, N.O. Fowler, Cardiovascular effects of anemia, Am.
Heart J. 83 (1972) 415–426.
[26] G.H. Gibbons, V.J. Dzau, The emerging concept of vascular remodeling, N. Engl.
J. Med. 330 (1994) 1431–1438.
[27] G.M. London, P.S. Parfrey, Cardiac disease in chronic uremia: pathogenesis,
Adv. Ren. Replace. Ther. 4 (1997) 194–211.
